Trial Profile
An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone) in Children With Autism Spectrum Disorder
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs Vatiquinone (Primary)
- Indications Autistic disorder; Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors BioElectron Technology
- 20 Jan 2022 Planned End Date changed from 1 Jan 2016 to 31 Jan 2016.
- 20 Jan 2022 Planned primary completion date changed from 1 Nov 2015 to 30 Nov 2015.
- 20 Jan 2022 Planned initiation date changed from 1 Sep 2014 to 31 Oct 2014.